@article{ref1,
title="Esketamine for treatment-resistant depression in adults",
journal="Cochrane database of systematic reviews",
year="2022",
author="Gastaldon, C. and Laurenzi, P.F. and Schoretsanitis, G. and Papola, D. and Cristea, I.A. and Naudet, F. and Ostuzzi, G. and Barbui, C.",
volume="2022",
number="1",
pages="-",
abstract="OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. The main aim of this Cochrane review is to assess the efficacy and tolerability of esketamine for treatment-resistant depression. Secondary aims are to assess the risk of specific adverse events during esketamine treatment, and its acceptability. Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.<p /><p>Language: en</p>",
language="en",
issn="1465-1858",
doi="10.1002/14651858.CD015071",
url="http://dx.doi.org/10.1002/14651858.CD015071"
}